

CIRM Funded Clinical Trials

A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer

Disease Area:	Colon Cancer
Investigator:	Mark Chao
Institution:	Forty Seven Inc.
CIRM Grant:	CLIN2-09577
Award Value:	\$10,234,048
Trial Sponsor:	Forty Seven Inc.
Trial Stage:	Phase 1/2
Trial Status:	Recruiting
Targeted Enrollment:	112
ClinicalTrials.gov ID:	NCT02953782



Mark Chao

Details:

Forty Seven, Inc. has developed an antibody therapy to block a protein called CD47 that is found on the surface of cancer cells. CD47 acts as a 'don't eat me' signal that tells immune cells not to eliminate the cancer cells. When this 'don't eat me' signal is blocked by the antibody, the cancer cells are 'eaten' and eliminated by the patient's immune cells. Forty Seven, Inc. will combine the anti-CD47 antibody with cetuximab – a drug used in the treatment of solid tumors – to treat patients with advanced colorectal cancer, hitting it with a 1-2 punch to kill the tumors and prevent any recurrence.

Design:

Single arm, non-randomized study.

Goal:

Safety. Dosing. Efficacy - objective response rate (ORR).

Updates:

This study is currently recruiting participants.

News Releases:

Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer

[Contact Trial Sponsor](#)

Source URL: <https://www.cirm.ca.gov/clinical-trial/phase-1b2-trial-anti-cd47-antibody-hu5f9-g4-combination-cetuximab-patients-solid>